• Chlamydia
  • Aerobic Gram-positive microorganisms: Staphylococcus aureus (methicillin-susceptible strains) Streptococcus pneumoniae (penicillin-susceptible strains) Streptococcus pyogenes Aerobic Gram-negative microorganisms Citrobacter koseri (Citrobacter diversus) Enterobacter aerogenes Escherichia coli Haemophilus influenzae Klebsiella pneumoniae Neisseria gonorrhoeae Proteus mirabilis Pseudomonas aeruginosa Other microorganisms: Chlamydia trachomatis In general, fluoroquinolones are well tolerated, with most side-effects being mild to moderate. (wikipedia.org)
  • Other microorganisms - Chlamydia pneumoniae, Mycoplasma pneumoniae Fluoroquinolones are generally well tolerated with most side effects being mild and serious adverse effects being rarely. (wikipedia.org)
  • Bacteria
  • Fluoroquinolones should only be prescribed when there is strong evidence of a condition caused by bacteria. (yourlegalguide.com)
  • Selection of a fluoroquinolone for the treatment or prevention of an infection should be limited to those conditions that are proven or strongly suspected to be caused by bacteria. (medpagetoday.com)
  • In contrast, the fluoroquinolones, which contain a fluorine atom, quickly achieve therapeutic concentration in plasma, tissues, and urine after oral administration and are active against some gram-positive bacteria. (thefreedictionary.com)
  • widely
  • After oral and parenteral administration, fluoroquinolones are widely distributed in most extracellular and intracellular fluids and are concentrated in the prostate, lungs, and bile. (merckmanuals.com)
  • drugs
  • Drugs in the fluoroquinolone family are used for treating urinary tract infections as well as other infectious diseases. (memorialhospitaljax.com)
  • Because St. John's wort and dong quai may also cause this problem, taking these herbal supplements during treatment with fluoroquinolone drugs might add to the risk. (memorialhospitaljax.com)
  • There are 21 classes of antibacterial drugs, with fluoroquinolones and three others penicillins, macrolides, and cephalosporins accounting for approximately 80 percent of all antibacterial prescriptions and sales. (yourlegalguide.com)
  • In a communication dated 15 August 2013, the following warning was posted on the FDA website: "FDA Drug Safety Communication: FDA requires label changes to warn of risk for possibly permanent nerve damage from antibacterial fluoroquinolone drugs taken by mouth or by injection. (wikipedia.org)
  • After lengthy testimony and discussion, the committees decided that the current labeling for these drugs was unacceptable, recommending additional study, discussion and action to make both patient and practitioners aware of the potential for both temporary and permanent adverse reactions to the drugs, particularly requiring physicians to be more completely informed that fluoroquinolones are not to be used as a first line of defense against the three maladies discussed. (wikipedia.org)
  • Even though this was the first fluoroquinolone, it is often overlooked when classifying the drugs within this class by generations and excluded from such a list. (wikipedia.org)
  • TB can usually be treated with a course of four standard, or first-line, anti-TB drugs (i.e., isoniazid, rifampin and any fluoroquinolone). (wikipedia.org)
  • Treatment of MDR-TB requires second-line drugs (i.e., fluoroquinolones, aminoglycosides, and others), which in general are less effective, more toxic and much more expensive than first-line drugs. (wikipedia.org)
  • Fluoroquinolone drugs, fluoroquinolone use has been linked to serious cases of toxic psychosis that have been reported to be irreversible and permanent, see adverse effects of fluoroquinolones The related quinoline derivative mefloquine (Lariam) has also been associated with psychosis. (wikipedia.org)
  • toxic
  • Although the mechanism is unknown, the sudden onset of some tendinopathies, occasionally after a single dose of a fluoroquinolone, suggests a direct toxic effect on collagen fibres. (bmj.com)
  • treatment
  • Because the risk of these serious side effects generally outweighs the benefits for patients with acute bacterial sinusitis, acute exacerbation of chronic bronchitis and uncomplicated urinary tract infections, the FDA has determined that fluoroquinolones should be reserved for use in patients with these conditions who have no alternative treatment options. (fluoridealert.org)
  • The label also contains new limitation-of-use statements to reserve fluoroquinolones for patients who do not have other available treatment options for acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis and uncomplicated urinary tract infections. (fluoridealert.org)
  • In November 2015, an FDA Advisory Committee discussed the risks and benefits of fluoroquinolones for the treatment of acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis and uncomplicated urinary tract infections based on new safety information. (fluoridealert.org)
  • The advisory committee concluded that the serious risks associated with the use of fluoroquinolones for these types of uncomplicated infections generally outweighed the benefits for patients with other treatment options. (fluoridealert.org)
  • Individuals with FQAD are defined as "U.S. patients who were reported to be previously healthy and prescribed an oral fluoroquinolone antibacterial drug for the treatment of uncomplicated sinusitis, bronchitis, or urinary tract infection (UTI). (wikipedia.org)
  • Adverse Reactions
  • There continues to be considerable debate as to whether or not this DNA damage is to be considered one of the mechanisms of action concerning the severe adverse reactions experienced by some patients following fluoroquinolone therapy. (wikipedia.org)
  • FQAD
  • Fluoroquinolone-Associated Disability ("FQAD") is an FDA formal review identification for a constellation of symptoms that have been identified in the FDA's Adverse Event Reporting System (FAERS) in review of data in the fluoroquinolone safety reports. (wikipedia.org)
  • cephalosporins
  • A U.S. Centers for Disease Control study found patients treated with fluoroquinolones experienced adverse events severe enough to lead to an emergency department visit more frequently than those treated with cephalosporins or macrolides, but less frequently than those treated with penicillins, clindamycin, sulfonamides, or vancomycin. (wikipedia.org)
  • Peripheral
  • On August 15, 2013 the FDA issued a Safety Announcement where they described that they are requiring the medication guides and drug labels for all fluoroquinolones to be updated and better describe the risk for peripheral neuropathy. (wikipedia.org)
  • drug
  • Today's action also follows a May 12, 2016, drug safety communication advising that fluoroquinolones should be reserved for these conditions only when there are no other options available due to potentially permanent, disabling side effects occurring together. (fluoridealert.org)